Journal of Gastrointestinal Cancer

, Volume 50, Issue 1, pp 84–90 | Cite as

Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer

  • Justin A. BarnesEmail author
  • Melissa L. Ellis
  • Sharon Hwang
  • Joan Emarine
  • Patti Merwin
  • Gregory D. Salinas
  • Benjamin L. Musher
Original Research



Pancreatic ductal adenocarcinoma (PDA) is associated with poor outcomes and presents oncologists with a myriad of clinical challenges. This study was conducted to assess oncologists’ practice patterns and to identify the greatest areas of need for future PDA continuing medical education (CME) programs.


Case vignettes have been validated as an effective tool to assess how physicians approach and treat a wide array of diseases. In order to assess practice patterns for resectable, locally advanced unresectable, and metastatic PDA, an online case vignette survey was distributed to practicing medical oncologists.


Responses from 150 US-practicing oncologists were analyzed, and several key opportunities for future CME programs were identified. For case 1 (patient with resectable PDA), 44% of oncologists did not select an evidence-based adjuvant chemotherapy regimen. For case 2 (patient with locally advanced PDA who develops metastases and neuropathy after first-line nab-paclitaxel/gemcitabine followed by chemoradiation), 57% of oncologists did not select an evidence-based second-line chemotherapy regimen, and 35% selected a regimen containing oxaliplatin, a chemotherapeutic known to cause neuropathy. For case 3 (patient with a pancreatic mass and liver metastases), only 34% of oncologists recommended a biopsy, chest imaging, and liver function tests which should be standard of care assessments with this presentation. For all three cases, clinical trial referral was selected by fewer than 5% of respondents.


This study identified appreciable discrepancies between oncologists’ recommendations and standard evidence-based guidelines. Well-designed CME programs may help to bridge the educational gaps identified and improve adherence to practice guidelines.


Pancreatic cancer Educational needs assessment Medical oncologist Survey 


Source of Funding

This study was financially supported by Celgene Corporation and conducted independently by CE Outcomes. J Emarine and P Merwin are both employees of Celgene and own stock in the corporation.

Compliance with Ethical Standards

Conflicts of Interest

All remaining authors have no conflicts to disclose.


  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(10):9–29. Scholar
  2. 2.
    National Comprehensive Cancer. Network NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma–version 1.2016. Fort Washington, PA: National Comprehensive Cancer Network; 2016, 27, 4, 289, 305. Scholar
  3. 3.
    Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62(4):277. CrossRefGoogle Scholar
  4. 4.
    Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–66. Scholar
  5. 5.
    Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65. Scholar
  6. 6.
    StatBite. U.S. pancreatic cancer rates. J Natl Cancer Inst. 2012;102(24):1822. Scholar
  7. 7.
    Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42(7):1157–63. CrossRefPubMedGoogle Scholar
  8. 8.
    Khorana AA, Manqu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56. Scholar
  9. 9.
    Balaban EP, Manqu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654–68. Scholar
  10. 10.
    Sohal DP, Manqu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(23):2784–96. Scholar
  11. 11.
    Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, et al. Failure to adhere to protocol specific radiation therapy guidelines was associated with decreased survival in RTOG 9704—a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radait Oncol Biol Phys. 2012;82(2):809–16. Scholar
  12. 12.
    Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford). 2012;14(8):539–47. Scholar
  13. 13.
    Laxdal OE, Jennett PA, Wilson TW, Salisbury GM. Improving physician performance by continuing medical education. Can Med Assoc J. 1978;118(9):1051–8.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Stein LS. The effectiveness of continuing medical education: eight research reports. J Med Educ. 1981;56(2):103–10.PubMedGoogle Scholar
  15. 15.
    Davis D, O’Brien MA, Freemantle N, et al. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282(9):867–74. Scholar
  16. 16.
    Mansouri M, Lockyer JA. Meta-analysis of continuing medical education effectiveness. J Contin Educ Heal Prof. 2007;27(1):6–15. Scholar
  17. 17.
    Davis D, Bordafe G, Moores LK, et al. Continuing medical education effect on practice performance: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines. Chest. 2009;135(3):42S–8S. Scholar
  18. 18.
    Accreditation Criteria. Accreditation Council for Continuing Medical Education. Accessed November 20 2017.
  19. 19.
    Peabody JW, Luck JM, Glassman P, et al. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA. 2000;283(13):1715–22. Scholar
  20. 20.
    Peabody JW, Luck J, Glassman P, Jain S, Hansen J, Spell M, et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med. 2004;141(10):771–80. Scholar
  21. 21.
    Luck J, Peabody JW, Lewis BL. An automatic scoring algorithm for computerized clinical vignettes: evaluating physician performance against explicit quality criteria. Int J Med Inform. 2006;75(10–11):710–7.Google Scholar
  22. 22.
    Peabody JW, Liu AA. Cross-national comparison of the quality of clinical care using vignettes. Health Policy Plan. 2007;22(5):294–302. Scholar
  23. 23.
    Neoptolemos JP, Palmer D, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet. 2017;389(10073):1011–24. Scholar
  24. 24.
    Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG III, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 2015;262(2):372–7. Scholar
  25. 25.
    Hyder O, Dodson RM, Nathan H, Schneider EB, Weiss MJ, Cameron JL, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg. 2013;148(12):1095–102. Scholar
  26. 26.
    Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19(5):1670–7. Scholar
  27. 27.
    Oettle H, Post S, Neuhas P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77. Scholar
  28. 28.
    Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(4):1473–81. Scholar
  29. 29.
    JP SDD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81. Scholar
  30. 30.
    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. CrossRefGoogle Scholar
  31. 31.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. Scholar
  32. 32.
    Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;21(2):16022. CrossRefGoogle Scholar
  33. 33.
    Hoos WA, James PM, Rahib L, et al. Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol. 2013;1(27):3432–8. CrossRefGoogle Scholar
  34. 34.
    Riall TS, Townsend CM, Kuo YF, et al. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer. 2010;116(4):930–9. Scholar
  35. 35.
    Chang DC, Zhang Y, Mukherjee D, Wolfgang CL, Schulick RD, Cameron JL, et al. Variations in referral patterns to high-volume centers for pancreatic cancer. J Am Coll Surg. 2009;209(6):720–6. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Justin A. Barnes
    • 1
    Email author
  • Melissa L. Ellis
    • 1
  • Sharon Hwang
    • 1
  • Joan Emarine
    • 2
  • Patti Merwin
    • 2
  • Gregory D. Salinas
    • 1
  • Benjamin L. Musher
    • 3
  1. 1.CE Outcomes, LLCBirminghamUSA
  2. 2.Celgene CorporationSummitUSA
  3. 3.Baylor College of MedicineHoustonUSA

Personalised recommendations